Shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) traded down 9.1% during mid-day trading on Tuesday . The company traded as low as $0.19 and last traded at $0.20, 2,262,438 shares traded hands during mid-day trading. An increase of 52% from the average session volume of 1,491,255 shares. The stock had previously closed at $0.22.
A number of equities research analysts have issued reports on the company. BMO Capital Markets cut their target price on Sienna Biopharmaceuticals to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, September 5th. ValuEngine upgraded Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $17.00.
The company has a quick ratio of 2.43, a current ratio of 2.43 and a debt-to-equity ratio of 1.11. The company has a market capitalization of $6.83 million, a P/E ratio of -0.06 and a beta of 2.67. The business has a 50 day simple moving average of $0.35 and a 200-day simple moving average of $1.01.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.16. Equities analysts forecast that Sienna Biopharmaceuticals Inc will post -3.1 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. FMR LLC raised its stake in shares of Sienna Biopharmaceuticals by 41.6% during the first quarter. FMR LLC now owns 4,489,690 shares of the company’s stock valued at $10,416,000 after purchasing an additional 1,318,675 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Sienna Biopharmaceuticals by 95.3% during the second quarter. Vanguard Group Inc. now owns 1,859,306 shares of the company’s stock valued at $1,617,000 after purchasing an additional 907,318 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Sienna Biopharmaceuticals by 92.1% during the second quarter. Renaissance Technologies LLC now owns 586,294 shares of the company’s stock valued at $510,000 after purchasing an additional 281,094 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Sienna Biopharmaceuticals during the second quarter valued at about $60,000. Finally, Jane Street Group LLC bought a new stake in shares of Sienna Biopharmaceuticals during the second quarter valued at about $50,000. Institutional investors own 45.87% of the company’s stock.
Sienna Biopharmaceuticals Company Profile (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Story: What does it mean to hold a stock in street name?
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.